PCOS Renamed PMOS in Australia: Monash, askPCOS and the Path Forward (2026)

Australia at the Heart of the Rename

Australia's role in the PMOS story is central, not peripheral. The Monash International PCOS Guideline — developed through the Monash Centre for Health Research and Implementation (MCHRI) at Monash University, Melbourne — is the most comprehensive evidence-based clinical framework for PCOS/PMOS management in the world. First published in 2018 and significantly updated in 2023, it was co-developed with ESHRE (the European Society of Human Reproduction and Embryology), endorsed by over 40 global health organizations, and forms the clinical backbone of the May 2026 PMOS consensus published in The Lancet.

Professor Helena Teede at Monash University led the guideline development process — the same research programme that also produced the askPCOS app, making Australia the primary source of both the clinical evidence and the patient-facing tools that define best practice in PMOS care globally.

For Australian patients, this means: the standard of care your GP, gynaecologist, or endocrinologist is working to is built on Australian research. The PMOS rename represents the culmination of that research agenda — a global correction to a name that, as Australian researchers demonstrated across multiple studies, had caused diagnostic confusion and delayed care for millions of patients worldwide.

The Monash International PCOS Guideline 2023

The Monash International PCOS Guideline 2023 is freely accessible at monash.edu/medicine/mchri/pcos/guideline. It covers 66 evidence-based recommendations across five domains: lifestyle, screening and diagnosis, emotional wellbeing, pharmacological treatment, and fertility management.

Key 2023 updates that are now standard of care in Australia:

• Letrozole replaces clomiphene as first-line pharmacological treatment for ovulation induction — reflecting the superior live birth rates (27.5% vs 19.1%) demonstrated in the landmark Legro 2014 NEJM trial.
• AMH as criterion 3 substitute: Elevated AMH (≥3.3 ng/mL) can replace pelvic ultrasound for diagnostic criterion 3 in adult women, reducing procedural burden.
• Mandatory psychological wellbeing assessment at diagnosis — addressing the 4× elevated anxiety and 3× elevated depression prevalence in PMOS.
• Insulin resistance screening for all phenotypes — not just overweight presentations — reflecting the 50–70% prevalence of insulin resistance regardless of BMI.

PMOS terminology update timeline: Monash University is expected to release an updated guideline addendum or revised edition incorporating PMOS terminology in 2026–2027, aligning with the international 3-year transition period agreed in the May 2026 consensus. The clinical content of the 2023 guideline remains fully current and applicable.

askPCOS App and Monash Digital Health Tools

The askPCOS app (askpcos.org) is the world's most downloaded PCOS/PMOS patient app, developed by the Monash MCHRI team. It provides evidence-based answers to over 60 frequently asked questions, developed directly from the Monash 2023 guideline. The app is free and available on iOS and Android.

Rebrand considerations: As of May 2026, Monash has not announced a formal rename of the askPCOS app to “askPMOS.” App rebrands are complex — they involve App Store listings, domain changes, SEO continuity, and clinical content review. Given Monash's institutional involvement in the May 2026 consensus, an update to the app's branding and content is expected, but no timeline has been confirmed.

Until any rebrand occurs, the askPCOS app content remains entirely valid for PMOS management. The clinical recommendations it delivers are based on the same Monash 2023 guideline that informed the PMOS rename.

Other Monash digital health tools available to Australian patients and healthcare providers include the PCOS Professional Resources toolkit at monash.edu, which provides GP-facing decision aids, patient handouts, and consultation frameworks that GPs can use in primary care PMOS management.

Medicare and PBS Billing

For Australian patients, a key practical question is whether the PMOS rename affects Medicare or Pharmaceutical Benefits Scheme (PBS) access. The short answer is: no immediate impact.

Medicare MBS item numbers: Medicare billing for PMOS-related services uses MBS item numbers linked to the type of consultation and procedure, not the specific condition name. Gynaecology consultations, pelvic ultrasounds, specialist referrals, and pathology requests (testosterone, AMH, HOMA-IR components) all have dedicated item numbers that are unaffected by the PCOS/PMOS terminology transition. ICD-10 code E28.2 remains the operative diagnostic code and is accepted by Medicare as-is during the 3-year transition period.

PBS prescriptions: Medications used in PMOS management — metformin, COCs, spironolactone, letrozole — are listed on the PBS under their respective indications. None of these listings reference the condition name directly in a way that would be affected by the rename. Metformin is listed for type 2 diabetes; its off-label use in PMOS is unchanged. Letrozole listings for ovulation induction continue under existing PBS criteria.

Enhanced Primary Care (EPC/CDM) plans: Australian GPs can establish a Chronic Disease Management plan for patients with PMOS, allowing Medicare-subsidised referrals to allied health professionals (dietitian, psychologist, exercise physiologist) — up to 5 visits per year. This pathway is unchanged by the rename and is highly relevant for the lifestyle-first management approach recommended in the Monash 2023 guideline.

Endocrine Society of Australia (ESA) and RANZCOG

The two primary specialist societies relevant to PMOS care in Australia are:

Endocrine Society of Australia (ESA)

The ESA has endorsed the Monash International PCOS Guideline 2023 and is expected to align formally with the PMOS terminology through a position statement in 2026. For Australian patients seeing an endocrinologist for PMOS-related insulin resistance, metabolic syndrome, or androgen excess, ESA-affiliated specialists are the most likely early adopters of PMOS terminology in clinical practice. ESA resources are available at endocrinology.org.au.

RANZCOG (Royal Australian and New Zealand College of Obstetricians and Gynaecologists)

RANZCOG has been a co-endorser of the Monash guideline since 2018. Their College Statement on PCOS, last updated in 2023, is expected to be revised in line with the PMOS rename, with a timeline paralleling the RCOG's response in the UK (Q3–Q4 2026). RANZCOG's training curriculum for O&G trainees will incorporate PMOS terminology in its next revision cycle.

For Australian patients: these society updates matter because they drive how your specialist refers to the condition in clinical correspondence, hospital discharge summaries, and referral letters — documents that form part of your permanent health record.

For Australian Patients: Your GP and Endocrinologist

The Australian primary care pathway for PMOS follows a well-established structure. Here is how to navigate it effectively in 2026.

Bulk billing and GP access

Most Australians access PMOS care first through a bulk-billed or mixed-billing GP. For initial assessment, your GP can order the full PMOS blood test panel — testosterone (total and free), SHBG, DHEAS, AMH, HOMA-IR components (fasting glucose and fasting insulin), full blood count, TSH, and lipids — all covered by Medicare. A pelvic ultrasound (MBS item 55065 for transabdominal, 55036 for transvaginal) can also be ordered by your GP.

Referral to endocrinologist or gynaecologist

Your GP can refer you to:

• Endocrinologist: for complex insulin resistance, metabolic syndrome, or when HOMA-IR is ≥3.0 and lifestyle + first-line pharmacotherapy has not achieved adequate response.
• Gynaecologist/Reproductive endocrinologist: for fertility concerns, ovulation induction with letrozole, or when cycle management (COCs, progesterone) requires specialist oversight.
• Dietitian via EPC plan: for structured nutritional support — the Mediterranean-pattern, low-GI diet is supported by the Monash guideline and Medicare subsidy makes this highly accessible.

Medicare Enhanced Primary Care plan for PMOS

If your GP diagnoses you with PMOS (coded as E28.2), you are eligible for a Chronic Disease Management (CDM) plan under Medicare's Team Care Arrangement structure. This funds up to 5 allied health visits per year (GP Management Plan + Team Care Arrangement). Key allied health professionals relevant to PMOS management: accredited practising dietitian, exercise physiologist, and psychologist. Ask your GP specifically about these plans — many GPs don't routinely offer them without a patient request.

Use our GP appointment summary builder to prepare a structured summary of your symptoms, test results, and goals before your consultation.

Frequently Asked Questions — PMOS in Australia

Does the PMOS rename affect my Medicare rebates in Australia?

No. Medicare billing in Australia uses MBS item numbers that are linked to clinical procedures, not condition names. The PMOS rename does not change existing MBS items for gynaecology consultations, ultrasounds, or specialist referrals. ICD-10 code E28.2 remains unchanged during the transition period.

Will the askPCOS app be renamed to askPMOS?

Monash University has not announced a formal rebrand of the askPCOS app as of May 2026. Given that Monash co-led the consensus behind the PMOS rename, an update to app branding is anticipated but no official timeline has been confirmed. The clinical content of the app — based on the Monash 2023 guideline — remains fully valid and applicable to PMOS.

How does the Monash guideline apply to Australian GPs?

The Monash International PCOS Guideline 2023 is the gold standard for PCOS/PMOS management in Australia and is endorsed by RANZCOG and the Endocrine Society of Australia. Australian GPs are expected to follow its recommendations on lifestyle intervention, letrozole for ovulation induction, screening for insulin resistance (HOMA-IR), and mental health support. The guideline is freely available at monash.edu/medicine/pcosguide.

Should I ask my specialist to update my diagnosis to PMOS?

It is not medically necessary. Your existing PCOS diagnosis is fully valid and no re-diagnosis is required. You can ask your GP or specialist to note "PMOS (formerly PCOS)" in your records if you prefer, but this is a personal choice and has no impact on Medicare rebates, referrals, or treatment pathways.

Where can Australian patients find PMOS support?

Key resources for Australian patients include: the askPCOS app (askpcos.org) developed by Monash University, the PCOS Association of Australia (PCOSAustralia.com), Jean Hailes for Women's Health (jeanhailes.org.au), and the Monash PCOS research team's patient resources at monash.edu/medicine/pcosguide. Your GP can also refer you to an endocrinologist or gynaecologist with PMOS expertise.